Latest news with #CapricorTherapeutics
Yahoo
21-05-2025
- Business
- Yahoo
Capricor Therapeutics, Inc.'s (CAPR): Analysts See 489% Upside Potential
We recently published an article titled . Capricor Therapeutics, Inc. (NASDAQ:CAPR) was one of the stocks that was covered in that article. Wall Street analysts believe CAPR has a 489% upside potential over the next 12 months. Test tubes filled with exosomes, representing exosome-based therapeutics. Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a biotechnology company that specializes in developing cell and exosome-based therapies for muscular and other diseases. Its flagship therapeutic candidate, CAP-1002, is in advanced clinical stages and is designed to address Duchenne muscular dystrophy (DMD), a severe genetic disorder that primarily affects muscles and the heart. CAP-1002 utilizes cardiosphere-derived cells (CDCs), which have been shown to modulate the immune system and reduce harmful tissue buildup, known as fibrosis, in the heart. This unique approach underscores the company's dedication to tackling complex medical conditions through innovative science. In addition to its work on CAP-1002, Capricor is actively advancing its exosome platform, which harnesses the potential of extracellular vesicles for therapeutic applications. Collaborations with esteemed institutions such as the National Institutes of Health (NIH), the U.S. Army Institute of Surgical Research, Johns Hopkins University, and Cedars-Sinai Medical Center exemplify its commitment to advancing research and development. These partnerships aim to broaden the scope of Capricor's initiatives, including the development of vaccines and therapeutics for infectious diseases and monogenic disorders. Capricor Therapeutics has demonstrated financial strength and strategic foresight. For the fourth quarter of 2024, the company reported revenues of $11.13 million, contributing to a total of $25.4 million in annual revenue. This growth is attributed to its pioneering efforts in cell therapy programs. With $78 million in cash reserves, Capricor is well-equipped to support ongoing clinical trials and future commercialization efforts, ensuring sustainability in its ambitious endeavors. In March, Reuters reported in an article Capricor Therapeutics (CAPR.O) announced that the U.S. Food and Drug Administration (FDA) intends to assemble a panel of external experts to review its cell therapy for a heart condition associated with Duchenne muscular dystrophy (DMD) before making a final decision. The company is pursuing full regulatory approval for its investigational cell therapy, deramiocel, as a potential treatment for patients with Duchenne muscular dystrophy cardiomyopathy. Following the news, the company's shares dropped nearly 15%, reaching $10.11 in morning trading. Wall Street analysts, however, have taken a favorable view of Capricor's prospects, recommending the stock as a 'Strong Buy.' The consensus twelve-month price target as of May 13, 2025, stands at $43.71, reflecting a remarkable upside potential of 489.89%. Overall, Capricor Therapeutics, Inc. (NASDAQ:CAPR) ranks 4th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of CAPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CAPR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Capricor Therapeutics, Inc.'s (CAPR): Analysts See 489% Upside Potential
We recently published an article titled . Capricor Therapeutics, Inc. (NASDAQ:CAPR) was one of the stocks that was covered in that article. Wall Street analysts believe CAPR has a 489% upside potential over the next 12 months. Test tubes filled with exosomes, representing exosome-based therapeutics. Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a biotechnology company that specializes in developing cell and exosome-based therapies for muscular and other diseases. Its flagship therapeutic candidate, CAP-1002, is in advanced clinical stages and is designed to address Duchenne muscular dystrophy (DMD), a severe genetic disorder that primarily affects muscles and the heart. CAP-1002 utilizes cardiosphere-derived cells (CDCs), which have been shown to modulate the immune system and reduce harmful tissue buildup, known as fibrosis, in the heart. This unique approach underscores the company's dedication to tackling complex medical conditions through innovative science. In addition to its work on CAP-1002, Capricor is actively advancing its exosome platform, which harnesses the potential of extracellular vesicles for therapeutic applications. Collaborations with esteemed institutions such as the National Institutes of Health (NIH), the U.S. Army Institute of Surgical Research, Johns Hopkins University, and Cedars-Sinai Medical Center exemplify its commitment to advancing research and development. These partnerships aim to broaden the scope of Capricor's initiatives, including the development of vaccines and therapeutics for infectious diseases and monogenic disorders. Capricor Therapeutics has demonstrated financial strength and strategic foresight. For the fourth quarter of 2024, the company reported revenues of $11.13 million, contributing to a total of $25.4 million in annual revenue. This growth is attributed to its pioneering efforts in cell therapy programs. With $78 million in cash reserves, Capricor is well-equipped to support ongoing clinical trials and future commercialization efforts, ensuring sustainability in its ambitious endeavors. In March, Reuters reported in an article Capricor Therapeutics (CAPR.O) announced that the U.S. Food and Drug Administration (FDA) intends to assemble a panel of external experts to review its cell therapy for a heart condition associated with Duchenne muscular dystrophy (DMD) before making a final decision. The company is pursuing full regulatory approval for its investigational cell therapy, deramiocel, as a potential treatment for patients with Duchenne muscular dystrophy cardiomyopathy. Following the news, the company's shares dropped nearly 15%, reaching $10.11 in morning trading. Wall Street analysts, however, have taken a favorable view of Capricor's prospects, recommending the stock as a 'Strong Buy.' The consensus twelve-month price target as of May 13, 2025, stands at $43.71, reflecting a remarkable upside potential of 489.89%. Overall, Capricor Therapeutics, Inc. (NASDAQ:CAPR) ranks 4th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of CAPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CAPR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey.
Globe and Mail
19-05-2025
- Business
- Globe and Mail
Exosomes Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Exosomes Pipeline Insight 2025 ' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Exosomes Pipeline. Dive into DelveInsight's comprehensive report today! @ Exosomes Pipeline Outlook Key Takeaways from the Exosomes Pipeline Report In April 2025, Aegle Therapeutics announced a study, with intra-subject paired- wound control, intended to assess the safety and preliminary efficacy of administering EVs derived from allogeneic MSCs to 10-50 cm2 wounds in RDEB subjects with wounds persisting for at least four weeks. DelveInsight's Exosomes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exosomes treatment. The leading Exosomes Companies such as Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others. Promising Exosomes Pipeline Therapies such as Anlotinib, AGLE 102, TISSEEL, and others. Stay ahead with the most recent pipeline outlook for Exosomes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Exosomes Treatment Drugs Exosomes Emerging Drugs Profile ExoFlo: Direct Biologics ExoFlo is an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product produced with a proprietary EV platform technology by Direct Biologics, LLC. Containing signaling molecules from bone marrow MSCs, ExoFlo harnesses the anti-inflammatory and regenerative properties of bone marrow MSCs without the cost, complexity, and limitations of scale associated with stem cell transplantation. EXO-CD24: Nano24 EXO-CD24 (CovenD24), is an investigational drug being developed by Nano24. The company has developed a new anti-inflammatory drug, EXO-CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF-kB pathway and the production of cytokines/chemokines. EXO-CD24 discriminates damage from pathogen-associated molecular patterns (DAMPs and PAMPs) and therefore does not interfere with viral clearance. EXO-CD24 was produced and purified from CD24-expressing 293-TREx cells. Exosomes displaying murine CD24 (mCD24) were also created. AGLE-102: Aegle Therapeutics AGLE 102 is an allogeneic-derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material, and regenerative healing factors to diseased and damaged tissue. The drug is being developed in the Phase I/II stage of its development for the treatment of Burns and Epidermolysis bullosa dystrophica. The drug is also in the preclinical stage of its development for the Graft vs. Host Disease. Progenza: Cambium Bio Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing. Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue. Adipose-derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types. EV-101: EV Therapeutics EV Therapeutics is a pre-clinical stage immuno-oncology biotechnology company devoted to developing first-in-class therapies based on modified tumor extracellular vesicles (mTEVs) to significantly transform cancer therapy and other unmet medical needs that are addressable with its proprietary technology platform. The leading candidate EV101, has demonstrated pre-clinical efficacy across solid tumor and advanced metastatic animal models both as a monotherapy and combination therapy with checkpoint inhibitors. The Exosomes Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment. Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market Explore groundbreaking therapies and clinical trials in the Exosomes Pipeline. Access DelveInsight's detailed report now! @ New Exosomes Drugs Exosomes Companies Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others. Exosomes Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Oral Intravenous Subcutaneous Parenteral Topical Exosomes Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Exosomes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Exosomes Market Drivers and Barriers Scope of the Exosomes Pipeline Report Coverage- Global Exosomes Companies- Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others. Exosomes therapies- Anlotinib, AGLE 102, TISSEEL, and others. Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Exosomes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Exosomes Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Exosomes : Overview Pipeline Therapeutics Therapeutic Assessment Exosomes – DelveInsight's Analytical Perspective Late Stage Products (Phase III) CAP-1002: Capricor Therapeutics Drug profiles in the detailed report….. Mid Stage Products (Phase II) Progenza: Regeneus Drug profiles in the detailed report….. Early Stage Products (Phase I/II) AGLE 102: Aegle Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Exosomes Key Companies Exosomes Key Products Exosomes - Unmet Needs Exosomes - Market Drivers and Barriers Exosomes - Future Perspectives and Conclusion Exosomes Analyst Views Exosomes Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Washington Post
13-05-2025
- Business
- Washington Post
Capricor: Q1 Earnings Snapshot
SAN DIEGO — SAN DIEGO — Capricor Therapeutics Inc. (CAPR) on Tuesday reported a loss of $24.4 million in its first quarter. The San Diego-based company said it had a loss of 53 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share.
Reuters
05-05-2025
- Business
- Reuters
US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy
May 5 (Reuters) - Capricor Therapeutics (CAPR.O), opens new tab said on Monday the U.S. Food and Drug Administration (FDA) plans to convene a panel of outside experts before deciding on the company's cell therapy for a heart condition related to Duchenne muscular dystrophy (DMD). Shares of the drug developer fell nearly 15% to $10.11 in morning trade. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. The company is seeking full approval for its experimental cell therapy, deramiocel, as a potential treatment for patients diagnosed with Duchenne muscular dystrophy cardiomyopathy. "We believe today's share weakness is unwarranted," H.C. Wainwright analyst Joseph Pantginis said, adding the opportunity to present at the meeting is "likely to strengthen the therapy's petition". The heart muscle disease is a leading cause of death among patients with DMD, a condition characterized by progressive skeletal and heart muscle weakness. The FDA is set to decide on the therapy by August 31, although the official date for the advisory panel meeting is yet to be set. The mass firings at the FDA under Health and Human Services Secretary Robert F. Kennedy Jr. have sparked concerns about potential delays in the drug review process. However, the FDA Chief Martin Makary said last week there were no plans for major reorganization at the agency and that it will meet its targets for completing reviews of new drugs despite the layoffs. In March, the company said that the FDA had not indicated whether an advisory committee would be necessary but said that it had been actively preparing for one.
